Sanofi agreed to acquire biopharmaceutical company Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx for approximately $1.7 billion and will also...
South Korea-based contract development and manufacturing organization (CDMO) SK Bioscience wants to expand its vaccine manufacturing plant located in Andong, South Korea...
Sanofi has entered into an agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to develop and commercialize the vaccine candidate for...
Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some...
Plans by major insulin producers Eli Lilly, NovoNordisk and Sanofi to drop their prices may be undercutting the US state of California’s state-backed generic insulin...
As part of what seems to be a general pattern of staff reductions in the pharmaceutical industry worldwide, a growing number of Western drugmakers are downsizing their...
The world's largest insulin producers, Eli Lilly, NovoNordisk and Sanofi are now marching (almost) in lockstep to reduce US market prices, but not without tossing...
Danish drugmaker Novo Nordisk has added its name to the list of insulin producers cutting prices for US retail buyers, following up on Eli Lilly’s announcement of price...
